PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing

A Phase 1, Open-label Trial to Evaluate Target Occupancy of CVL-231 at Muscarinic Receptors Type 4 in Brain Following Single Oral Doses Using Positron Emission Tomography in Healthy Adult Subjects

PET Trial to Evaluate Target Occupancy of CVL-231 at Muscarinic Receptors Type 4 in Brain Following Oral Dosing

Study Overview

• Status: Completed
• Conditions: Schizophrenia
• Intervention / Treatment: Drug: CVL-231; Drug: CVL-231; Drug: CVL-231

Detailed Description

CVL-231 is a muscarinic acetylcholine receptor (mAChR) activator that selectively binds to the M4 muscarinic receptor subtype (M4 mAChR). CVL-231 is being developed for treatment of psychosis in schizophrenia. The aim of this trial is to characterize the relationship between the M4 receptor occupancy in different regions of the brain following a single oral doses of CVL-231 in healthy adult subjects by positron emission tomography (PET) using the radioligand [11C]MK-6884.

• Study Type: Interventional
• Enrollment (Actual): 15
• Phase: Phase 1

Contacts and Locations

Study Locations

• Belgium
  • Leuven, Belgium, 3000
    • UZ Leuven
• United States
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
      • Massachusetts General Hospital Translational and Clinical Research Centers

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Healthy male subjects and female subjects of nonchildbearing potential, ages 18 to 55 years, inclusive, at the time of signing the ICF
• Sexually active men with a pregnant or a nonpregnant partner of childbearing potential must agree to use a double-barrier method of birth control, including a condom, and practice contraception during treatment and through 7 days post dose
• Capable of providing informed consent and following study requirements

Exclusion Criteria:

• Subjects who answer yes on the C-SSRS or, in the opinion of the investigator, present a serious risk of suicide
• Subjects with a current history of significant cardiovascular, pulmonary, gastrointestinal, renal, hepatic, metabolic, hematological, immunological, or neurological disease

• Subjects with a 12-lead ECG demonstrating either of the following (average of 3 ECGs obtained at the Screening Visit):

  • QT interval corrected for heart rate using Fridericia's formula >450 msec
  • Left ventricular hypertrophy
• Orthostatic hypotension, which is defined as a decrease of ≥20 mmHg in systolic blood pressure and/or a decrease of ≥10 mmHg in diastolic blood pressure after at least 3 minutes of standing compared with the immediately previous supine/semi-recumbent blood pressure at Screening or at the prescan time point prior to baseline PET scan.
• Subjects with a current or past personal history of any psychiatric disorder as classified by DSM-5 criteria or immediate family members with any psychiatric disorder as classified by DSM-5 criteria that require treatment
• Subjects with a history of substance or alcohol-use disorder (DSM-5 criteria) within 2 years prior to signing the ICF
• Subjects with other abnormal laboratory test results, vital sign results, or ECG findings
• Subjects who currently use or have used tobacco or nicotine-containing products within 30 days prior to signing the ICF
• Subjects with history of prior radiation exposure for research purposes within the past year such that participation in this study would place them over FDA limits for annual radiation exposure (5 rem per year)
• Subjects with any anatomical abnormality in the head that would either preclude or tend to confound the analysis of study data, including any clinically significant abnormal findings from MRI of the head
• Current, past or anticipated exposure to radiation in the workplace
• Any subject with a significant acute illness within 7 days prior to administration of study drug or have had a major illness or hospitalization within 1 month prior to administration of study drug
• Any subject who, in the opinion of the sponsor, investigator, or medical monitor, should not participate in the trial

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: CVL-231	Drug: CVL-231; Cohort 1: 30mg dose of CVL-231; Other Names: PF-06852231; Drug: CVL-231; Cohort 2: CVL-231 dose to be decided based on results of Cohort 1 or trial may be concluded; Other Names: PF-06852231; Drug: CVL-231; Cohort 3: CVL-231 dose to be decided based on results of Cohorts 1 and/or 2; Other Names: PF-06852231

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
M4 receptor occupancy in the striatum following single oral doses of CVL-231 in healthy adult subjects	Fraction of M4 receptors occupied by CVL-231 doses	Day 1

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Treatment-emergent adverse events		Upto 9 weeks
Number of subjects with Clinically significant changes in Electrocardiogram		Screening, Pre-scan, Day-1, Day 1 (T=0hour), Day 1 (T=0.5hour), Day 1 (T=3.0hour), Day 2 (T=24hour), Day 10
Number of subjects with clinical significant Clinical laboratory assessments		Screening, Pre-scan, Day-1, Day 2 (T=24hour)
Number of subjects with Clinically significant changes in Vital signs		Screening, Day-1 (T=1hour), Day-1 (T=1.5hour), Day-1, Day 1 (T=0hour), Day 1(T=1.5hour), Day 1 (T=3hour), Day 1 (T=6hr), Day 1 (T=8.0), Day 2 (T-=24hr), Day 10
Number of subjects with clinically significant Physical and neurological examination results		Screening, Day-1 pre-scan, Day-1, Day 2
Suicidality assessed using the Columbia-Suicide Severity Rating Scale	Suicidality will be monitored during the trial using the Columbia - Suicide Severity Rating Scale (C-SSRS)	Screening, Day-1, Day 2, Day 10
Cmax during scan for CVL-231	Max CVL-231 concentration during PET scan	Day 1 (0.5, 1.5 and 2.0 hours)
AUCscan duration for CVL-231	AUC for CVL-231 during PET scan	Day 1 (0.5, 1.5 and 2.0 hours)
Cavg/Scan duration for CVL-231	Average CVL-231 concentration during scan	Day 1 (0.5, 1.5 and 2.0 hours)
Model estimated Emax and EC50 at M4 receptors in striatum for CVL-231	Model estimated values for Maximum possible binding (Emax) and CVL-231 concentrations required from hal-maximal binding (EC50)	Day 1

Collaborators and Investigators

• Sponsor: Cerevel Therapeutics, LLC
• Investigators: Study Director: Matthew Leoni, MD, MBA, Cerevel Therapeutics, LLC

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2021
• Primary Completion (Actual): July 14, 2023
• Study Completion (Actual): July 14, 2023

Study Registration Dates

• First Submitted: February 1, 2021
• First Submitted That Met QC Criteria: March 5, 2021
• First Posted (Actual): March 8, 2021

Study Record Updates

• Last Update Posted (Actual): July 27, 2023
• Last Update Submitted That Met QC Criteria: July 25, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Keywords: Schizophrenia; PET; Healthy Volunteer
• Additional Relevant MeSH Terms: Mental Disorders; Schizophrenia Spectrum and Other Psychotic Disorders; Schizophrenia
• Other Study ID Numbers: CVL-231-1002

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No